Nicholson Nur 4
4 · Apellis Pharmaceuticals, Inc. · Filed Sep 19, 2023
Insider Transaction Report
Form 4
Nicholson Nur
Chief Technical Officer
Transactions
- Exercise/Conversion
Common Stock
2023-09-18$29.76/sh+9,719$289,237→ 73,634 total - Sale
Common Stock
2023-09-18$42.21/sh−9,719$410,224→ 63,915 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-09-18−9,719→ 115,281 totalExercise: $29.76Exp: 2030-08-16→ Common Stock (9,719 underlying) - Sale
Common Stock
2023-09-18$46.15/sh−10,631$490,589→ 53,284 total
Footnotes (4)
- [F1]This transaction was executed in multiple trades at prices ranging from $46.200 - $46.250. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F2]This transaction was executed in multiple trades at prices ranging from $46.140 - $46.240. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]This includes 412 shares from 04/30/2023 ESPP purchase.
- [F4]This stock option was granted on August 17, 2020 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant date, subject to continued service.